

Darbepoetin alfa– Biosimilar Insight, 2022

<https://marketpublishers.com/r/D415137E7713EN.html>

Date: January 2022

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: D415137E7713EN

Abstracts

This report can be delivered to the clients within 24 Hours

DelveInsight's, "Darbepoetin alfa– Biosimilar 2022," report provides comprehensive insights about 10+ companies and 10+ marketed and pipeline drugs in Darbepoetin alfa Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Darbepoetin alfa Understanding

Darbepoetin alfa: Overview

Human erythropoietin with 2 aa substitutions to enhance glycosylation (5 N-linked chains), 165 residues (MW=37 kD). Produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology. Darbepoetin alfa stimulates erythropoiesis by the same mechanism as endogenous erythropoietin. Erythropoietin interacts with progenitor stem cells to increase red cell production. Binding of erythropoietin to the erythropoietin receptor leads to receptor dimerization, which facilitates activation of JAK-STAT signaling pathways within the cytosol. Activated STAT (signal transducers and activators of transcription) proteins are then translocated to the nucleus where they serve as transcription factors which regulate the activation of specific genes involved in cell division or differentiation.

Darbepoetin alfa Biosimilars: Drugs Chapters

This segment of the Darbepoetin alfa report encloses its detailed analysis of various drugs in different stages of clinical development, including marketed, phase III, II, I and preclinical. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Darbepoetin alfa Biosimilars: Marketed Drugs

Darbatitor: Torrent Pharmaceuticals

Darbatitor 40mcg Injection is used in the treatment of anemia that may have occurred due to chronic kidney disease or chemotherapy. It works by stimulating the bone marrow to produce more red blood cells.

Further product details are provided in the report.....

Darbepoetin alfa Biosimilars: Emerging Drugs

CJ-40001: HK inno.N

HK inno.N is developing CJ-40001 for the treatment of Anaemia.

Further product details are provided in the report.....

Darbepoetin alfa: Therapeutic Assessment

This segment of the report provides insights about the different Darbepoetin alfa biosimilars segregated based on following parameters that define the scope of the report, such as:

Major Players in Darbepoetin alfa

There are approx. 10+ key companies which are developing the therapies for Darbepoetin alfa.

Phases

DelveInsight's report covers around 10+ products under different phases of clinical development like

Marketed stage products

Late stage products (BLA Filed and Phase III)

Mid-stage products (Phase II and

Early-stage products (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Darbepoetin alfa pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Subcutaneous

Intravenous

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal antibodies

Peptide

Protein

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Darbepoetin alfa: Pipeline Development Activities

The report provides insights into different therapeutic candidates in marketed, phase III, II, I and preclinical stage. It also analyses Darbepoetin alfa biosimilars drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Darbepoetin alfa biosimilar drugs.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Darbepoetin alfa R&D. The therapies under development are focused on novel approaches to treat/improve Darbepoetin alfa.

In March 2020, CJ Healthcare, a subsidiary of Kolmar Korea, announced that it has changed the company name to HK inno.N on the occasion of its 36th anniversary.

Darbepoetin alfa Biosimilars Report Insights

Darbepoetin alfa Biosimilar Pipeline Analysis

Therapeutic Assessment

Sales Assessment

Unmet Needs

Impact of Drugs

Darbepoetin alfa Biosimilar Report Assessment

Marketed Product profiles

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Sales Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Darbepoetin alfa Biosimilars?

How many Darbepoetin alfa biosimilars are developed by each company?

How many emerging biosimilars are in mid-stage, and late-stage?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Darbepoetin alfa biosimilars therapeutics?

What are the clinical studies going on for Darbepoetin alfa biosimilars and their

status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Torrent Pharmaceuticals

Reliance Life Sciences

Nichi-Iko Pharmaceutical

Kyowa Kirin

Kissei Pharmaceutical

Dr Reddy's

Dong-A ST

CJ Healthcare

Cipla

Chong Kun Dang Pharmaceutical

Biocad

Avesthagen Pharma

3SBio

Key Products

Darbatitor

DarbeRel

AP 032

Darbepoetin Alfa Injection Syringe

JR-131

Cresp

DA?3880

CJ-40001

Actorise

CKD-11101

BCD 066

Avdesp

NuPIAO

Contents

1. KEY INSIGHTS

2. DARBEPOETIN ALFA BIOSIMILARS: SNAPSHOT

3. EXECUTIVE SUMMARY

3.1. Overview

3.2. The Basics of Biologics.

3.3. Biosimilars are not the Same as Generic Drugs

3.4. Economics of Biosimilars – the Promise of Lower Prices, but at What Cost?

3.5. What Patients Need to Know About Biosimilars

4. REGULATORY OUTLOOK FOR BIOSIMILARS

4.1. North America

4.1.1. US

4.1.2. Canada

4.2. Europe

4.3. Asia Pacific

4.3.1. China

4.3.2. India

4.3.3. Japan

4.3.4. South Korea

4.3.5. Australia

4.4. Rest Of The World

4.4.1. Brazil

4.4.2. Mexico

4.4.3. Argentina

4.4.4. Saudi Arabia

*More Countries would be added in the final report

5. DARBEPOETIN ALFA (REFERENCE PRODUCT: ARANESP)

5.1. Drug Profile

5.2. Product Overview

5.3. Regulatory Approvals and Launch

5.4. Indications

- 5.5. Mechanism of Action
- 5.6. Dosage and Administration
- 5.7. Dosage and Strengths
- 5.8. Dose Modification
- 5.9. Route of Synthesis
- 5.10. Pharmacology
- 5.11. Pharmacodynamics
- 5.12. Pharmacokinetics
- 5.13. Adverse Reactions
- 5.14. Product Snapshot
- 5.15. Development Milestones

6. RESEARCH AND DEVELOPMENT

- 6.1. Clinical Trials Information
- 6.2. Safety and Efficacy

7. ARANESP BIOSIMILAR: EMERGING OPPORTUNITIES

8. DARBEPOETIN ALFA: BIOSIMILARS ASSESSMENT

- 8.1. Assessment by Product Type
- 8.2. Assessment by Route of Administration
- 8.3. Assessment by Molecule type
- 8.4. Sales Assessment

9. DARBEPOETIN ALFA BIOSIMILARS PROFILES: BY COMPANY

- 9.1.1. Torrent Pharmaceuticals
 - 9.1.1.1. Darbatitor: Torrent Pharmaceuticals
 - 9.1.1.1.1. Product Information
 - 9.1.1.1.2. Research and Development
 - 9.1.1.1.3. Other Development Activities
 - 9.1.1.1.4. General Description Table
- 9.1.2. Reliance Life Sciences
 - 9.1.2.1. DarbeRel : Reliance Life Sciences
 - 9.1.2.1.1. Product Information
 - 9.1.2.1.2. Research and Development
 - 9.1.2.1.3. Other Development Activities

9.1.2.1.4. General Description Table

9.1.3. CJ Healthcare

9.1.3.1. CJ-40001: CJ Healthcare

9.1.3.1.1. Product Information

9.1.3.1.2. Research and Development

9.1.3.1.3. Other Development Activities

9.1.3.1.4. General Description Table

*More Companies and products would be added in the final report

10. DARBEPOETIN ALFA BIOSIMILARS: COMPARATIVE LANDSCAPE: BY COMPANY

11. DARBEPOETIN ALFA BIOSIMILARS: COMPETITIVE LANDSCAPE

11.1.1. Overview

11.1.2. Market Share Analysis

11.1.3. Competitive Scenario

11.1.3.1. Product Launches and approval

11.1.3.2. Partnerships, Collaborations and Agreements

11.1.3.3. Acquisitions

11.1.3.4. Expansions

11.1.3.5. Patent Expiration of Biologics

*More information would be added in the final report

12. MARKET DRIVERS

13. MARKET BARRIERS

14. SWOT ANALYSIS

15. APPENDIX

15.1. Research Methodology

15.1.1. Coverage

15.1.2. Secondary Research

16. BIBLIOGRAPHY

17. DELVEINSIGHT CAPABILITIES

18. DISCLAIMER

19. ABOUT DELVEINSIGHT

I would like to order

Product name: Darbepoetin alfa– Biosimilar Insight, 2022

Product link: <https://marketpublishers.com/r/D415137E7713EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/D415137E7713EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970